This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xiong, L. Articles by Mankin, A. S. Search for Related Content PubMed PubMed Citation Articles by Xiong, L. Articles by Mankin, A. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2005, p. 281-288, Vol. 49, No. 1
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.1.281-288.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Binding Site of the Bridged Macrolides in the Escherichia coli Ribosome

Center for Pharmaceutical Biotechnology, University of Illinois, Chicago, Illinois,¹ ENANTA Pharmaceuticals, Inc., Watertown, Massachuestts²

Received 31 May 2004/ Returned for modification 9 August 2004/ Accepted 27 September 2004

Ketolides represent the latest group of macrolide antibiotics. Tight binding of ketolides to the ribosome appears to correlate with the presence of an extended alkyl-aryl side chain. Recently developed 6,11-bridged bicyclic ketolides extend the spectrum of platforms used to generate new potent macrolides with extended alkyl-aryl side chains. The purpose of the present study was to characterize the site of binding and the action of bridged macrolides in the ribosomes of Escherichia coli. All the bridged macrolides investigated efficiently protected A2058 and A2059 in domain V of 23S rRNA from modification by dimethyl sulfate and U2609 from modification by carbodiimide. In addition, bridged macrolides that carry extended alkyl-aryl side chains protruding from the 6,11 bridge protected A752 in helix 35 of domain II of 23S rRNA from modification by dimethyl sulfate. Bridged macrolides efficiently displaced erythromycin from the ribosome in a competition binding assay. The A2058G mutation in 23S rRNA conferred resistance to the bridged macrolides. The U2609C mutation, which renders E. coli resistant to the previously studied ketolides telithromycin and cethromycin, barely affected cell susceptibility to the bridged macrolides used in this study. The results of the biochemical and genetic studies indicate that in the E. coli ribosome, bridged macrolides bind in the nascent peptide exit tunnel at the site previously described for other macrolide antibiotics. The presence of the side chain promotes the formation of specific interactions with the helix 35 of 23S rRNA.

This article has been cited by other articles:

• Skripkin, E., McConnell, T. S., DeVito, J., Lawrence, L., Ippolito, J. A., Duffy, E. M., Sutcliffe, J., Franceschi, F. (2008). R{chi}-01, a New Family of Oxazolidinones That Overcome Ribosome-Based Linezolid Resistance. Antimicrob. Agents Chemother. 52: 3550-3557 [Abstract] [Full Text]  
• Stucki, A., Gerber, P., Acosta, F., Cottagnoud, M., Cottagnoud, P., Jiang, L., Nguyen, P., Wachtel, D., Wang, G., Phan, L. T. (2008). Effects of EDP-420 on penicillin-resistant and quinolone- and penicillin-resistant pneumococci in the rabbit meningitis model. J Antimicrob Chemother 61: 665-669 [Abstract] [Full Text]